Wells Fargo pulled back 1.5% on Wednesday to $86.42. Options traders are the most defensive they've been in two weeks.
The put/call ratio hit 1.38 on July 22. That's 2.2 standard deviations above its 20-day mean of 1.28. The ratio has climbed steadily since mid-July, when it sat near 1.22. It remains well below the 52-week high of 1.58, but the directional move is notable given the stock had only recently recovered from its post-earnings dip.
The PCR trend tells a clean story. WFC spent most of June above 1.38 — a period that coincided with pre-earnings caution. It then compressed through mid-July as the stock recovered. Now it's climbing again. That two-week low in PCR around July 14–16 was the calm after the earnings storm. The current re-expansion suggests some traders are hedging the recovery.
The stock is off 1.2% on the week. Peers are mixed: BAC gained 1.3% on the day while KEY fell 1.6%. WFC's move isn't dramatically out of step with the sector, but it's underperforming the large-cap end of the peer group.
The borrow story has unwound almost entirely. Cost to borrow is now 0.24%, down 75% from the brief spike above 0.93% seen around the July 14 earnings date. Availability is essentially unlimited — the lending pool is showing no strain. Short interest sits at 0.91% of the free float. That's a low level and telling no directional story on its own.
The brief CTB spike was a noise event, not the start of a squeeze. It has fully normalized.
The mean analyst price target is $99.80 — roughly 15% above current levels. That gap has persisted since the post-earnings recalibration. BofA holds a $102 Buy. UBS sits at $104 Buy. Both were set before results and remain intact. Keefe, Bruyette & Woods trimmed to $94 from $98, and Baird raised to $92 from $85, keeping Neutral. The dispersion of targets reflects a stock where the bull and bear cases are genuinely contested.
Next earnings: October 13.
See the live data behind this article on ORTEX.
Open WFC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
